---
title: "CASI Pharmaceuticals Receives China NMPA Approval for Phase 1/2 Clinical Trial of CID-103 in Renal Allograft AMR"
description: "CASI Pharmaceuticals Inc. has received approval from the China National Medical Products Administration (NMPA) for a Phase 1/2 clinical trial of CID-103, aimed at treating renal allograft antibody-med"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/272709819.md"
published_at: "2026-01-15T14:00:35.000Z"
---

# CASI Pharmaceuticals Receives China NMPA Approval for Phase 1/2 Clinical Trial of CID-103 in Renal Allograft AMR

> CASI Pharmaceuticals Inc. has received approval from the China National Medical Products Administration (NMPA) for a Phase 1/2 clinical trial of CID-103, aimed at treating renal allograft antibody-mediated rejection (AMR). The U.S. FDA has also approved an Investigational New Drug application for a Phase 1 study of CID-103 in adults with chronic active renal allograft AMR. These approvals enable CASI to conduct clinical studies in both China and the U.S.

CASI Pharmaceuticals Inc. announced that it has received regulatory approval from the China National Medical Products Administration (NMPA) for a Phase 1⁄2 clinical trial application (CTA) to study CID-103 for the treatment of renal allograft antibody-mediated rejection (AMR). Additionally, the U.S. Food and Drug Administration (FDA) has previously approved an Investigational New Drug (IND) application for a Phase 1 study of CID-103 in adults with chronic active renal allograft AMR. These approvals allow CASI Pharmaceuticals to proceed with clinical studies of CID-103, a potential anti-CD38 monoclonal antibody, in both China and the United States. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CASI Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1127439) on January 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CASI.US - CASI Pharmaceuticals](https://longbridge.com/en/quote/CASI.US.md)
- [CASIF.US - CASI PHARMACEUTICALS INC](https://longbridge.com/en/quote/CASIF.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Syndax 制药｜10-K：2025 财年营收 1.72 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/277095834.md) |
| Syndax 制药｜8-K：2025 财年 Q4 营收 68.73 百万美元超过预期 |  | [Link](https://longbridge.com/en/news/277094758.md) |
| UroGen 制药｜8-K：2025 财年营收 1.1 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/277469966.md) |
| 汉方制药冲刺港股：9 个月营收 8 亿 利润 1.5 亿 为秦文基家族企业 | 汉方制药股份有限公司近日递交招股书，计划在港交所上市。公司在 2025 年前 9 个月营收 8 亿元，利润 1.45 亿元。汉方制药专注于中医药产品，结合传统中医与现代医药。公司由秦文基家族控制，秦文基为董事长，持股 90%。预计 2023 | [Link](https://longbridge.com/en/news/276957195.md) |
| Xenon 制药｜8-K：2025 财年营收 7.5 百万美元 |  | [Link](https://longbridge.com/en/news/277094902.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.